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Abstract
Background: Hedgehog (HH) signaling plays a critical role in normal cellular processes, in normal mammalian
gastrointestinal development and differentiation, and in oncogenesis and maintenance of the malignant phenotype in a
variety of human cancers. Increasing evidence further implicates the involvement of HH signaling in oncogenesis and
metastatic behavior of colon cancers. However, genomic approaches to elucidate the role of HH signaling in cancers in
general are lacking, and data derived on HH signaling in colon cancer is extremely limited.
Methodology/Principal Findings: To identify unique downstream targets of the GLI genes, the transcriptional regulators of
HH signaling, in the context of colon carcinoma, we employed a small molecule inhibitor of both GLI1 and GLI2, GANT61, in
two human colon cancer cell lines, HT29 and GC3/c1. Cell cycle analysis demonstrated accumulation of GANT61-treated
cells at the G1/S boundary. cDNA microarray gene expression profiling of 18,401 genes identified Differentially Expressed
Genes (DEGs) both common and unique to HT29 and GC3/c1. Analyses using GenomeStudio (statistics), Matlab (heat map),
Ingenuity (canonical pathway analysis), or by qRT-PCR, identified p21
Cip1 (CDKN1A) and p15
Ink4b (CDKN2B), which play a role
in the G1/S checkpoint, as up-regulated genes at the G1/S boundary. Genes that determine further cell cycle progression at
G1/S including E2F2, CYCLIN E2 (CCNE2), CDC25A and CDK2, and genes that regulate passage of cells through G2/M
(CYCLIN A2 [CCNA2], CDC25C, CYCLIN B2 [CCNB2], CDC20 and CDC2 [CDK1], were down-regulated. In addition, novel genes
involved in stress response, DNA damage response, DNA replication and DNA repair were identified following inhibition of
HH signaling.
Conclusions/Significance: This study identifies genes that are involved in HH-dependent cellular proliferation in colon
cancer cells, and following its inhibition, genes that regulate cell cycle progression and events downstream of the G1/S
boundary.
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Introduction
Hedgehog (HH) signaling plays a critical role in a variety of
normal cellular processes. It is pivotal in embryogenesis, regulation
of the epithelial-to-mesenchymal transition, the patterning of a
diverse range of vertebrate structures in a variety of organs,
maintenance of adult tissue homeostasis, tissue repair, cellular
proliferation, and in cell survival [1,2,3,4,5,6,7,8,9]. The canonical
HH pathway is also critical to normal mammalian gastrointestinal
development, where it is involved in the coordinate regulation of
differentiation of normal intestinal villi [10,11,12]. Thus, in the
normal gastrointestinal tract, HH ligands are induced in the
differentiated cells around the villous surface, generating a
negative feedback loop to inhibit canonical WNT signaling in
the basal cells of the crypt, thereby protecting differentiated cells
from the proliferative effects of WNT [13]. Activation of the
canonical HH signaling pathway comprises the binding of HH
ligands to the membrane receptor Patched (PTCH1), which
becomes internalized leading to the activation of the signaling
molecule Smoothened (SMO) via release from PTC-mediated
suppression. SMO activates the final arbiter of HH signaling, the
GLI family of transcription factors that bind to the GAC-
CACCCA-like consensus binding element in promoter sequences
to transcriptionally regulate HH target genes [3,14,15]. GLI1 and
GLI2, the transcriptional activators of HH signaling, possess
distinct as well as overlapping functions that involve activator
(GLI1 and GLI2) or repressor (GLI2) activities [16]; however,
their roles in the regulation of HH-driven cellular proliferation,
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GLI1 has been considered the most reliable marker of HH
pathway activity, however GLI2 appears to be the primary
activator of HH signaling, with GLI1 as a transcriptional target of
GLI2 [3,7], leading to augmentation of HH signaling both
quantitatively as well as qualitatively [16]. An important feature of
GLI proteins is that their biological activity is context-dependent,
influenced by the cellular environment [17,18].
Activation of the canonical HH signaling cascade is aberrantly
activated and well known to play a critical role in oncogenesis and
maintenance of the malignant phenotype in several types of
human cancers. Such activation involves amplification of GLI1 or
GLI2, mutations in PTC or SMO, or dysregulated gene
expression [3,4]; these malignant cells are also sensitive to the
small molecule inhibitor that targets SMO, cyclopamine
[4,19,20,21,22,23]. Colon carcinomas are thought to derive from
constitutive activation of WNT signaling by mutation of the APC
or b-CATENIN genes, while the involvement of the HH signaling
pathway is not as clear. In gastrointestinal malignancies,
transcriptional up-regulation of HH ligands has been identified
as the predominant activator of HH signaling in these diseases
(reviewed in [3]). In addition, there is emerging evidence that HH
signaling is involved in colorectal carcinogenesis [24,25], colon
carcinoma stem cell self renewal, and in the metastatic behavior of
advanced colon cancers [26]. However, genomic approaches to
elucidate the role of HH signaling in cancers in general are
lacking, regulatory genes downstream of GLI1 and GLI2 that
function in cellular proliferation, survival, and maintenance of the
malignant HH phenotype remain incompletely characterized [5],
and data derived on HH signaling in colon cancer is extremely
limited.
Cellular proliferation is driven by progression of cells through
the cell cycle consisting of sequential passage through G1, S, G2
and M phases. Cyclin-dependent kinases (CDKs) associate with
cyclins to drive the cell cycle machinery [27,28]. Thus, CDK2
associates with CYCLIN E at the G1/S transition and with
CYCLIN A during S-phase, CDK4 and CDK6 bind to CYCLIN
D during progression at G1/S, while CDC2 complexes with
CYCLIN A at G2, and with CYCLIN B during the G2/M
transition. CDC25 family members also regulate cell cycle
progression through dephosphorylation of the CDKs [29,30].
CDK inhibitors, including p21
Cip1 [29,31] and p15
Ink4b [[32],
bind to cyclin-CDK complexes during the cell cycle transition, in
particular at G1/S (p21
Cip1, p15
Ink4b;[32]) and G2/M
(p21
Cip1;[29]), and can also induce cell cycle arrest at the G1/S
boundary following cytostatic signals through functional inhibition
of cyclin-CDK complexes. The E2F family of transcription factors
also regulates the expression of genes required for the G1/S
transition, in particular genes involved in the activation of the
DNA replication machinery, and DNA repair [33].
cDNA microarray technology has provided the ability to study
the expression of thousands of genes simultaneously, and is an
important tool in the dissection of signal transduction pathways.
For the HH signaling cascade, HH/GLI target gene expression
has been examined following EGF stimulation [6] or inducible
GLI1 [16] or GLI2 [9] gene activation in human keratinocytes, or
in GLI1-induced cell transformation [7]. To identify unique
downstream targets of the GLI genes that function in cellular
proliferation in the context of colon carcinoma, we employed a
small molecule inhibitor of both GLI1 and GLI2, GANT61,
identified in a cell-based small molecule screen for inhibitors of
GLI1-mediated transcription [34]. GANT61 acts in the nucleus to
block GLI1 function, inhibits both GLI1- and GLI2- mediated
transcription, and demonstrates a high degree of selectivity for
HH/GLI signaling [34]. Thus, GANT61 acts downstream of
cyclopamine (targeting SMO) to inhibit the final determinants of
HH transcriptional regulation.
In two human colon carcinoma cell lines, HT29 and GC3/c1,
inhibiting the HH signaling pathway using GANT61 decreased
expression of GLI1, GLI2 and the HH ligand receptor, PTCH1,
and inhibited proliferation by inducing cellular accumulation at
the G1/S boundary 24 hr after treatment, determined by flow
cytometric analysis. On further detailed analysis using cDNA
microarray gene expression profiling and quantitative Real-Time
PCR, p21
Cip1 (CDKN1A) and p15
Ink4b (CDKN2B), that can elicit
the G1/S checkpoint, were up-regulated, while genes that further
determine entry from G1 to S-phase including E2F2, CYCLIN E2
(CCNE2), CDC25A and CDK2 were decreased in expression.
Concomitant with decreased G1 to S-phase progression, decreased
expression of CYCLIN A2 (CCNA2), CDC25C, CYCLIN B2
(CCNB2), CDC20 and CDC2 (CDK1), that regulate the passage
of cells through G2/M were also demonstrated. Additional novel
genes that are involved in stress response, and the response to
DNA damage, not previously identified following termination of
HH signaling in human cancer cells, include the early response
genes DDIT2 (GADD45G), DDIT3 (GADD153), DDIT4
(REDD1), PPP1R15A (GADD34) and ATF3 that were signifi-
cantly up-regulated. Genes involved in DNA synthesis and repair
(TYMS, TOP2A, TK1, POLE, POLE2), and additional novel
genes involved in S-phase progression or DNA damage responses
that were significantly down-regulated, include KIAA0101 (p15
[PAF]), Replication Factor C variants 2, 3, 4, 5, CDT1, the E2F
transcription factors CDCA4 and TFDP1, MDC1, FANCD2,
PCNA, and the genes involved in DNA repair, RAD51C
(XRCC3), RAD54B, RAD51 and HELLS. This study has
therefore identified genes that are regulated during the termina-
tion of HH-dependent cellular proliferation and survival in colon
cancer cells, and involves genes associated with G1/S-phase arrest,
DNA damage and stress responses.
Results
GANT61 induces down-regulated expression of GLI
genes and accumulation of human colon carcinoma cells
at G1/S
In HT29 and GC3/c1 cells treated with GANT61 (20 mM) for
up to 48 hr, expression of the target genes GLI1 and GLI2 were
both down-regulated, and also the HH ligand receptor PTCH1, as
determined by qRT-PCR (Figure 1A). Subsequently, HT29 or
GC3/c1 cells were treated, in duplicate, with GANT61 (20 mM)
followed by PI staining and flow cytometric analysis for the
determination of cell cycle distribution between G1, S and G2/M
phases (Figure 1B). In both cell lines, cells accumulated in G1,
24 hr after treatment with GANT61. In GANT61-treated HT29
cells, a 20% increase in G1-phase cells was associated with a
corresponding decrease in cells within the G2/M phase (14%) and
in S-phase (5%), consistent with a G1/S checkpoint arrest. In
GC3/c1 cells, an 8% increase in G1-phase cells at 24 hr after
GANT61 treatment also corresponded with a similar reduction in
cells in the G2/M phase of the cell cycle (Figure 1B).
cDNA microarray analyses identify changes in gene
expression both common and unique to HT29 and
GC3/c1 following GANT61 treatment
To delineate the changes in gene expression in HT29 and
GC3/c1 human colon carcinoma cell lines in response to
treatment with the GLI1/GLI2 antagonist, GANT61, the
HH-Dependent Gene Expression
PLoS ONE | www.plosone.org 2 October 2010 | Volume 5 | Issue 10 | e13054Figure 1. Expression of GLI1, GLI2, PTCH1 and cell cycle distribution of HT29 and GC3/c1 cells. Cells were treated for up to 48 hr with
GANT61 (20 mM) or with 0.2% DMSO (vehicle control). (A) qRT-PCR of GLI1, GLI2 and PTCH1 genes from time 0 to 48 hr. (B) DNA was extracted at
24 hr after treatment, stained with propidium iodide, and subsequently analyzed for the effects of inhibition of HH signaling on phase distribution of
cells within the cell cycle by flow cytometry.
doi:10.1371/journal.pone.0013054.g001
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treated with vehicle (0.2% DMSO) and in cells treated with
GANT61 (20 mM) for 24 hr. Genes with a False Discovery Rate
(FDR)-adjusted p-value of ,0.001 and fold change .1.5 were
considered Differentially Expressed Genes (DEGs) induced by
GANT61 relative to the vehicle control, of which 1,368 genes
were differentially expressed in HT29, and 1,002 genes in GC3/c1
cells (Figure 2). 755 genes or 558 genes were up-regulated, and 613
or 444 genes were down-regulated, in HT29 and GC3/c1 cells,
respectively. 763 and 397 genes were differentially expressed and
unique to HT29 or GC3/c1, respectively. Of the 763 DEGs
unique to HT29, 459 (60%) were up-regulated and 304 (40%)
were down-regulated. Similarly, of the 397 DEGs unique to GC3/
c1, 262 (66%) were up-regulated and 135 (34%), down-regulated.
In contrast, 605 genes representing 3.4% of all genes were
differentially expressed that were common to both cell lines; of
these, 296 were up-regulated (49%), and 309 (51%) were down-
regulated (Figure 2). All genes common to both HT29 and GC3/
c1 that were significantly up-regulated or down-regulated
(p,0.001) are listed in Tables 1 and 2, respectively.
Modulation of canonical signaling pathways following
inhibition of HH signaling
Genes with significant changes in expression following
GANT61 treatment were assigned to different canonical signaling
pathways and subjected to Ingenuity Pathway Analysis (IPA),
where the resulting 1,368 DEGs in HT29 and 1,002 DEGs in
GC3/c1 were mapped to networks defined by the IPA database
(Figure 3). For the mapped DEGs including both up- and down-
regulated genes, the 15 most significantly altered canonical
pathways in HT29 demonstrated –log(p-value) ranging from
2.045 to 9.025, and in GC3/c1 from 2.32 to 7.509. Of the 15
pathways involving genes significantly down-regulated, 12 were
common to both cell lines. The 3 common pathways with the
greatest differential down-regulated expression include genes
involved in the DNA damage response, cell cycle checkpoint
control, and mitosis. Other pathways down-regulated involved the
G1/S and G2/M DNA damage checkpoints, DNA precursor
metabolism, and cell signaling involving different pathways
including those involved in cancers, which also demonstrate 3
signatures unique to either HT29 or GC3/c1 (Figure 3). Of the 15
pathways involving genes that are the most significantly up-
regulated, 8 are common to both HT29 and GC3/c1, and 7
represent unique pathways for each cell line, demonstrating more
diversity in patterns of up-regulated gene expression (Figure 3).
The up-regulated pathways common to both cell lines include the
metabolism-related such as steroids, pyruvate, glycolysis glutathi-
one, or glycerolipid, and not directly related to the control of
cellular proliferation.
Genes that demonstrate differential fold change patterns
in GANT61-treated HT29 and GC3/c1 cells
Fold change patterns of most highly DEGs in HT29 and GC3/
c1 were selected, analyzed and displayed in a heat map to evaluate
and compare similarity and differences in differential expression
between the two cell lines treated with GANT61 (Figure 4). In
addition to genes with diverse functions that are not directly
related to HH-dependent proliferation, up-regulated genes that
influence the G1/S transition and subsequent cell cycle progres-
sion, and that are common to both cell lines, include CDKN1A,
and the DNA-damage-inducible transcripts 3 and 4 (DDIT3 and
DDIT4). A considerably greater number of genes involved in
cellular proliferation and cell cycle transition through the G1/S
boundary, S-phase progression, and the G2/M transition, were
significantly down-regulated in expression, and common to both
cell lines. These include CDC6 (involved at G1/S), three genes
that drive entry into and passage through S-phase (CCNE2, E2F2)
and G2 (CCNA2), genes involved in DNA replication and repair
(TYMS, POLE, TOP2A, TK1, POLE2), and two genes that
regulate mitosis (AURKB, CDC20; Figure 4, asterisks).
Of the 296 up-regulated genes, in addition to the genes
comparably represented in the heat map that include DDIT3
(GADD153) and DDIT4 (REDD1), additional novel DNA
damage-inducible transcripts were also identified and include
DDIT2 (GADD45G), PPP1R15A (GADD34) and ATF3 (Table 1).
TP53INP1, which can regulate cell cycle arrest, and TP53INP2,
identified in cell death responses, were also up-regulated. Of the
309 genes significantly down-regulated in response to GANT61,
novel genes identified include KIAA0101 (p15[PAF]), Replication
Factor C variants 2, 3, 4, 5, CDT1, the E2F transcription factors
CDCA4 and TFDP1, MDC1, PCNA, FANCD2, and the genes
involved in DNA repair, RAD51C (XRCC3), RAD54B, RAD51
and HELLS (Table 2).
Differentially expressed genes involved in the G1/S and
G2/M transitions
To further evaluate the genes involved in control of cell cycle
progression in human colon carcinoma cells following GANT61
treatment, 10 genes involved in the G1/S or G2/M transitions,
identified by IPA, were selected for further examination. Genes
required at the G1/S boundary for G1/S transition, or for the
induction of a G1/S checkpoint following cytostatic signals,
Figure 2. Venn diagram summarizing Differentially Expressed
Genes (DEGs) in GANT61-treated HT29 and GC3/c1 cells. Cells
were treated with GANT61 (20 mM) or vehicle alone (0.2% DMSO) for
24 hr, and total RNA extracted as described in Materials and Methods.
Changes in gene expression were determined by cDNA microarray gene
profiling using the Illumina Human-ref8 V3.0 Bead-Chip array. Genes
with a False Discovery Rate (FDR)-adjusted p-value (p,0.001) and fold
change .1.5 were considered DEGs. Upper panel: up-regulated genes.
Lower panel: down-regulated genes. Differential expression for the
total, unique up-regulated, unique down-regulated, common up-
regulated, and common down-regulated DEGs, are shown.
doi:10.1371/journal.pone.0013054.g002
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ACCESSION
NUMBER
GENE
SYMBOL DEFINITION Fold Change
ACCESSION
NUMBER
GENE
SYMBOL DEFINITION Fold Change
HT29 GC3/c1 HT29 GC3/c1
NM_080489.3 SDCBP2 syndecan binding protein 12.42 10.83 NM_001008213.1 OPTN optineurin 2.63 2.37
NM_001042483.1 NUPR1 nuclear protein 1 7.96 3.53 NM_000431.1 MVK mevalonate kinase 2.61 2.77
NM_021187.2 CYP4F11 cytochrome P450 7.73 4.27 NM_001550.2 IFRD1 interferon-related
developmental
regulator 1
2.60 1.84
NM_001001870.1 C17orf91 chromosome 17 open
reading frame 91
6.79 3.82 NM_025130.2 HKDC1 hexokinase domain
containing 1
2.58 4.46
NM_004864.1 GDF15 growth differentiation
factor 15
6.61 3.43 NM_002461.1 MVD mevalonate (diphospho)
decarboxylase
2.57 5.36
NM_004083.4 DDIT3 DNA-damage-inducible
transcript 3
6.36 2.35 NM_021626.1 SCPEP1 serine carboxypeptidase 1 2.55 1.79
NM_005130.3 FGFBP1 fibroblast growth
factor binding protein 1
5.86 41.19 NM_012424.2 RPS6KC1 ribosomal protein
S6 kinase
2.53 2.03
NM_022060.2 ABHD4 abhydrolase domain
containing 4
5.65 3.07 NM_052839.2 PANX2 pannexin 2 2.53 5.61
NM_015526.1 CLIP3 CAP-GLY domain
containing linker protein 3
5.25 2.74 NM_021173.2 POLD4 polymerase
(DNA-directed)
2.51 1.71
NM_000389.2 CDKN1A cyclin-dependent kinase
inhibitor 1A
5.21 2.02 NM_020400.4 LPAR5 lysophosphatidic acid
receptor 5
2.50 2.17
NM_002298.2 LCP1 lymphocyte cytosolic
protein 1
5.02 8.60 NM_007075.3 WDR45 WD repeat domain 45 2.50 1.61
NM_019058.2 DDIT4 DNA-damage-inducible
transcript 4
4.91 3.91 NM_001909.3 CTSD cathepsin D 2.50 1.68
NM_031412.2 GABARAPL1 GABA(A) receptor-associated
protein like 1
4.73 4.81 NM_022157.2 RRAGC Ras-related GTP
binding C
2.48 2.80
NM_033285.2 TP53INP1 tumor protein p53 inducible
nuclear protein 1
4.71 2.80 NM_138573.2 NRG4 neuregulin 4 2.48 2.69
NM_001001342.1 BLOC1S2 biogenesis of lysosome-
related organelles complex-1
4.68 3.95 NM_201545.1 LGALS8 lectin 2.46 2.81
NM_153282.1 HYAL1 hyaluronoglucosaminidase 1 4.57 22.29 NM_175738.3 RAB37 RAB37, member RAS
oncogene family
2.40 3.53
NM_012385.1 P8 p8 protein 4.57 4.01 NM_012257.3 HBP1 HMG-box transcription
factor 1
2.40 1.65
NM_016061.1 YPEL5 yippee-like 5 4.39 3.98 NM_001083617.1 RB1CC1 RB1-inducible coiled-coil 1 2.39 1.68
NM_145693.1 LPIN1 lipin 1 4.39 3.59 NM_153341.1 RNF19B ring finger protein 19B 2.38 1.61
NM_019600.1 KIAA1370 KIAA1370 4.13 2.73 NM_003129.3 SQLE squalene epoxidase 2.38 3.03
NM_021009.3 UBC ubiquitin C 4.08 7.52 NM_018045.5 BSDC1 BSD domain containing 1 2.38 2.34
NM_002084.3 GPX3 glutathione peroxidase 3 4.05 2.99 NM_003376.4 VEGFA vascular endothelial
growth factor A
2.37 2.09
NM_003256.2 TIMP4 TIMP metallopeptidase
inhibitor 4
4.04 2.02 NM_007028.3 TRIM31 tripartite motif-containing 31 2.37 6.54
NM_198336.1 INSIG1 insulin induced gene 1 4.02 9.90 NM_000527.2 LDLR low density lipoprotein receptor 2.35 3.83
NM_002517.2 NPAS1 neuronal PAS domain
protein 1
3.95 2.76 NM_024717.3 MCTP1 multiple C2 domains,
transmembrane 1
2.33 2.28
NM_001040619.1 ATF3 activating transcription
factor 3
3.90 1.86 NM_198833.1 SERPINB8 serpin peptidase inhibitor 2.32 2.07
NM_006096.2 NDRG1 N-myc downstream
regulated gene 1
3.89 2.63 NM_023039.2 ANKRA2 ankyrin repeat, family A
(RFXANK-like)
2.31 1.82
NM_003670.1 BHLHB2 basic helix-loop-helix
domain containing
3.82 3.68 NM_025047.1 ARL14 ADP-ribosylation
factor-like 14
2.30 6.15
NM_002130.6 HMGCS1 3-hydroxy-3-methylglutaryl-
Coenzyme A synthase 1
3.75 6.54 NM_001080391.1 SP100 SP100 nuclear antigen 2.29 1.90
NR_003086.1 HSD17B7P2 hydroxysteroid (17-beta)
dehydrogenase 7
pseudogene 2
3.74 2.83 NM_002395.3 ME1 malic enzyme 1 2.29 2.31
NM_001013680.1 LOC401233 similar to HIV TAT specific
factor 1
3.74 2.10 NM_001360.2 DHCR7 7-dehydrocholesterol reductase 2.29 2.73
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HT29 GC3/c1 HT29 GC3/c1
NM_006918.4 SC5DL sterol-C5-desaturase 3.68 3.41 NM_032421.2 CLIP2 CAP-GLY domain containing
linker protein 2
2.27 1.79
NM_182980.2 OSGIN1 oxidative stress induced
growth inhibitor 1
3.55 4.48 NM_014039.2 C11orf54 chromosome 11 open reading
frame 54
2.27 1.62
NM_025182.2 KIAA1539 KIAA1539 3.49 2.62 NM_017585.2 SLC2A6 solute carrier family 2 2.27 2.35
NM_018677.2 ACSS2 acyl-CoA synthetase short-
chain family member 2
3.46 4.68 NM_014330.2 PPP1R15A protein phosphatase 1 2.26 1.63
NM_001034850.1 FAM134B family with sequence
similarity 134
3.44 1.90 NM_145306.2 C10orf35 chromosome 10 open reading
frame 35
2.26 2.19
NM_153742.3 CTH cystathionase (cystathionine
gamma-lyase)
3.38 2.13 NM_003831.3 RIOK3 RIO kinase 3 2.25 1.93
NM_021158.3 TRIB3 tribbles homolog 3 3.34 3.71 NM_006997.2 TACC2 transforming, acidic coiled-coil
containing protein 2
2.25 1.95
NM_000434.2 NEU1 sialidase 1 3.28 2.00 NM_001006932.1 RPS6KA2 ribosomal protein S6 kinase 2.24 1.68
NM_001005404.3 YPEL2 yippee-like 2 3.22 2.40 NM_000574.2 CD55 CD55 molecule 2.23 1.84
NM_004508.2 IDI1 isopentenyl-diphosphate
delta isomerase 1
3.21 4.78 NM_018310.2 BRF2 subunit of RNA polymerase III
transcription initiation factor
2.23 2.14
NM_003151.2 STAT4 signal transducer and
activator of transcription 4
3.18 3.85 NM_001491.2 GCNT2 glucosaminyl (N-acetyl)
transferase 2
2.22 4.08
NM_005165.2 ALDOC aldolase C 3.16 2.44 NM_003567.2 BCAR3 breast cancer anti-estrogen
resistance 3
2.21 1.79
NM_014331.3 SLC7A11 solute carrier family 7 3.16 2.54 NM_005488.1 TOM1 target of myb1 2.20 1.89
NM_000104.2 CYP1B1 cytochrome P450 3.15 2.41 NM_004462.3 FDFT1 farnesyl-diphosphate
farnesyltransferase 1
2.19 2.73
NM_002340.3 LSS lanosterol synthase 3.14 3.15 NM_019116.2 UBFD1 ubiquitin family domain
containing 1
2.19 1.90
NM_078487.2 CDKN2B cyclin-dependent kinase
inhibitor 2B
3.13 2.13 NM_007105.1 SLC22A18AS solute carrier family 22 2.18 1.81
NM_002201.4 ISG20 interferon stimulated
exonuclease gene 20kDa
3.12 1.91 NM_182491.1 ZFAND2A zinc finger 2.17 2.17
NM_016315.2 GULP1 GULP, engulfment
adaptor PTB domain
containing 1
3.11 4.39 NM_181785.2 SLC46A3 solute carrier family 46 2.17 2.00
NM_017983.4 WIPI1 WD repeat domain 3.09 2.40 NM_024866.4 ADM2 adrenomedullin 2 2.16 1.77
NM_024165.1 PHF1 PHD finger protein 1 3.07 2.42 NM_021133.2 RNASEL ribonuclease L 2.15 2.28
NM_001995.2 ACSL1 acyl-CoA synthetase
long-chain family member 1
3.06 2.86 NM_032548.2 ABTB1 ankyrin repeat and BTB (POZ)
domain containing 1
2.14 1.58
NM_004354.1 CCNG2 cyclin G2 3.05 2.64 NM_002153.1 HSD17B2 hydroxysteroid (17-beta)
dehydrogenase 2
2.14 2.98
NM_020739.2 CCPG1 cell cycle progression 1 3.04 1.88 NM_006033.2 LIPG lipase 2.13 2.86
NM_001017369.1 SC4MOL sterol-C4-methyl oxidase-like 3.03 4.04 NM_020919.2 ALS2 amyotrophic lateral sclerosis 2 2.11 1.77
NM_001031744.1 LOC158160 hypothetical protein
LOC158160
3.02 2.35 NM_014701.2 KIAA0256 KIAA0256 gene product 2.11 2.30
NM_032409.2 PINK1 PTEN induced putative
kinase 1
2.98 2.44 NM_001222.2 CAMK2G calcium/calmodulin-
dependent protein kinase
2.11 2.12
NM_003811.2 TNFSF9 tumor necrosis factor
(ligand) superfamily
2.98 3.04 NM_015271.2 TRIM2 tripartite motif-containing 2 2.11 1.79
NM_002357.2 MXD1 MAX dimerization protein 1 2.93 2.30 NM_174936.2 PCSK9 proprotein convertase
subtilisin/kexin type 9
2.11 4.18
NM_000777.2 CYP3A5 cytochrome P450 2.92 1.77 NM_015713.3 RRM2B ribonucleotide reductase M2 B 2.10 1.66
NM_001098500.1 KIAA1217 KIAA1217 2.88 3.16 NM_005749.2 TOB1 transducer of ERBB2 2.09 1.58
NM_022119.3 PRSS22 protease 2.84 3.27 NM_004419.3 DUSP5 dual specificity phosphatase 5 2.08 3.61
NM_004669.2 CLIC3 Homo sapiens chloride
intracellular channel 3
2.80 6.19 NM_033028.2 BBS4 Bardet-Biedl syndrome 4 2.08 2.04
NM_080491.1 GAB2 GRB2-associated binding
protein 2
2.79 2.06 NM_001286.2 CLCN6 chloride channel 6 2.07 2.18
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NM_178270.1 ATG4A ATG4 autophagy
related 4 homolog A
2.79 1.92 XM_001132495.1 SLC26A11 PREDICTED:solute
carrier family 26
2.07 1.87
NM_002770.2 PRSS2 protease, serine,
2 (trypsin 2)
2.79 1.64 NM_172070.2 ZNF650 zinc finger protein 650 2.07 1.90
NM_182608.2 ANKRD33 ankyrin repeat
domain 33
2.74 1.91 NM_004567.2 PFKFB4 6-phosphofructo-2-
kinase/fructose-2
2.07 1.93
NM_006705.2 GADD45G growth arrest and
DNA-damage-inducible
2.74 3.01 NM_002555.3 SLC22A18 solute carrier family 22 2.06 1.62
NM_012326.2 MAPRE3 microtubule-associated
protein
2.73 2.16 NM_001010990.1 HERPUD1 homocysteine-inducible,
ubiquitin-like domain
member 1
2.06 1.63
NM_001013251.1 SLC3A2 solute carrier family 3 2.72 2.40 NM_198867.1 ALKBH6 alkB, alkylation repair
homolog 6
2.06 1.65
NM_016243.2 CYB5R1 cytochrome b5 reductase 1 2.72 2.52 NM_000271.3 NPC1 Niemann-Pick disease 2.05 2.18
NM_198129.1 LAMA3 laminin 2.65 3.36 NM_006454.2 MXD4 MAX dimerization protein 4 2.05 1.80
NM_000228.2 LAMB3 laminin 2.65 2.27 NM_021194.2 SLC30A1 solute carrier family 30 2.03 1.73
NM_006608.1 PHTF1 putative homeodomain
transcription factor 1
2.64 2.38 NM_173843.1 IL1RN interleukin 1 receptor
antagonist
2.03 10.01
NM_021229.3 NTN4 netrin 4 2.03 2.47 NM_152271.3 LONRF1 LON peptidase N-terminal
domain and ring finger 1
1.72 3.04
NM_002064.1 GLRX glutaredoxin 2.03 1.75 NM_003314.1 TTC1 tetratricopeptide repeat
domain 1
1.72 1.55
NM_005896.2 IDH1 isocitrate dehydrogenase 1 2.02 2.37 NM_005920.2 MEF2D myocyte enhancer factor 2D 1.71 1.85
NM_144498.1 OSBPL2 oxysterol binding
protein-like 2
2.01 1.81 NM_016410.2 CHMP5 chromatin modifying
protein 5
1.71 2.14
NM_005115.3 MVP major vault protein 1.99 1.82 NM_001748.3 CAPN2 calpain 2 1.70 2.16
NM_023938.4 C1orf116 chromosome 1 open
reading frame 116
1.98 3.06 NM_004344.1 CETN2 centrin 1.70 1.54
NM_024311.2 MFSD11 major facilitator superfamily
domain containing 11
1.98 1.80 NM_177947.2 ARMCX3 armadillo repeat containing,
X-linked 3
1.70 1.76
NM_004433.3 ELF3 E74-like factor 3 1.97 3.72 NM_000158.2 GBE1 glucan 1.69 1.73
NM_031229.2 RBCK1 RanBP-type and C3HC4-type
zinc finger containing 1
1.97 4.21 NM_052873.1 C14orf179 chromosome 14 open
reading frame 179
1.69 1.52
NM_005564.3 LCN2 lipocalin 2 1.97 4.19 NM_020310.2 MNT MAX binding protein 1.69 1.51
NM_002956.2 CLIP1 CAP-GLY domain containing
linker protein 1
1.96 1.62 NM_015367.2 BCL2L13 BCL2-like 13 1.69 1.88
NM_005562.1 LAMC2 laminin, gamma 2 1.96 2.01 NM_001005474.1 NFKBIZ nuclear factor of kappa light
polypeptide gene enhancer
1.69 1.72
NM_000332.2 ATXN1 ataxin 1 1.96 1.86 NM_021202.1 TP53INP2 tumor protein p53 inducible
nuclear protein 2
1.69 1.89
NM_001206.2 KLF9 Kruppel-like factor 9 1.96 2.19 NM_138448.2 ACYP2 acylphosphatase 2 1.68 2.03
NM_173359.3 EIF4E3 eukaryotic translation
initiation factor 4E family
member 3
1.95 2.01 NM_003729.1 RTCD1 RNA terminal phosphate
cyclase domain 1
1.67 1.61
NM_003565.1 ULK1 unc-51-like kinase 1 1.95 1.57 NM_030912.2 TRIM8 tripartite motif-containing 8 1.67 1.70
NM_012161.2 FBXL5 F-box and leucine-rich
repeat protein 5
1.95 2.27 NM_018202.3 TMEM57 transmembrane protein 57 1.67 1.88
NM_001079864.1 TAX1BP1 Tax1 (human T-cell leukemia
virus type I) binding protein 1
1.93 1.66 NM_018297.2 NGLY1 N-glycanase 1 1.66 1.68
NM_005063.4 SCD stearoyl-CoA desaturase 1.93 4.44 NM_183399.1 RNF14 ring finger protein 14 1.66 1.87
NM_145279.4 MOBKL2C MOB1, Mps One Binder
kinase activator-like 2C
1.92 2.58 NM_032357.2 CCDC115 coiled-coil domain
containing 115
1.66 1.63
NM_004055.4 CAPN5 calpain 5 1.91 2.05 NM_172037.2 RDH10 retinol dehydrogenase 10 1.66 2.20
NM_175932.1 PSMD13 proteasome (prosome,
macropain) 26S subunit
1.91 2.14 NM_012287.3 CENTB2 centaurin 1.65 1.62
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NM_002885.1 RAP1GAP RAP1 GTPase activating
protein
1.91 2.02 NM_018178.3 GOLPH3L golgi phosphoprotein 3-like 1.65 1.64
NM_145245.2 EVI5L ecotropic viral integration
site 5-like
1.90 1.69 NM_025147.3 COQ10B coenzyme Q10 homolog B 1.64 1.54
NM_021242.3 MID1IP1 MID1 interacting protein 1 1.89 1.78 NM_006285.2 TESK1 testis-specific kinase 1 1.64 1.61
NM_006503.2 PSMC4 proteasome (prosome,
macropain) 26S subunit
1.89 2.16 NM_001018102.1 GRINL1A glutamate receptor 1.64 1.92
NM_005975.2 PTK6 protein tyrosine kinase 6 1.88 1.97 NM_005476.3 GNE glucosamine
(UDP-N-acetyl)-2-epimerase
1.64 2.98
NM_207304.1 MBNL2 muscleblind-like 2 1.88 1.63 NR_002204.1 FTHL11 ferritin, heavy polypeptide-like
11 on chromosome 8
1.63 1.79
NM_000859.1 HMGCR 3-hydroxy-3-methylglutaryl-
Coenzyme A reductase
1.88 2.46 NM_053067.1 UBQLN1 ubiquilin 1 1.63 1.56
NM_021021.2 SNTB1 syntrophin 1.88 1.64 NM_005895.3 GOLGA3 golgi autoantigen 1.63 1.58
NM_032667.4 BSCL2 Bernardinelli-Seip congenital
lipodystrophy 2
1.87 1.73 NM_037370.1 CCNDBP1 cyclin D-type binding-
protein 1
1.63 1.50
NM_006022.2 TSC22D1 TSC22 domain family 1.87 2.40 NM_001042430.1 FAM164C family with sequence
similarity 164
1.62 2.01
NM_012478.3 WBP2 WW domain binding
protein 2
1.87 1.67 NM_004751.1 GCNT3 glucosaminyl (N-acetyl)
transferase 3
1.62 3.99
NM_031476.2 CRISPLD2 cysteine-rich secretory protein
LCCL domain containing 2
1.87 2.57 NM_004428.2 EFNA1 ephrin-A1 1.61 2.10
NM_017921.1 NPLOC4 nuclear protein localization 4
homolog
1.87 1.74 NM_007193.3 ANXA10 annexin A10 1.61 2.36
NM_015508.3 TIPARP TCDD-inducible poly(ADP-
ribose) polymerase
1.86 1.75 NM_018180.2 DHX32 DEAH (Asp-Glu-Ala-His) box
polypeptide 32
1.61 1.52
NM_001376.2 DYNC1H1 dynein, cytoplasmic 1, heavy
chain 1
1.86 1.50 NM_020202.2 NIT2 nitrilase family 1.61 1.62
NM_144693.1 ZNF558 zinc finger protein 558 1.86 1.98 NM_032169.4 ACAD11 acyl-Coenzyme A
dehydrogenase family
1.61 1.73
NM_003344.2 UBE2H ubiquitin-conjugating
enzyme E2H
1.85 2.04 NM_147223.2 NCOA1 nuclear receptor
coactivator 1
1.60 1.57
NM_152528.1 WDSUB1 WD repeat, sterile alpha
motif and U-box domain
containing 1
1.85 1.74 NM_002203.3 ITGA2 integrin 1.59 2.49
NM_001225.3 CASP4 caspase 4, apoptosis-related
cysteine peptidase
1.85 1.97 NM_018317.1 TBC1D19 TBC1 domain family 1.59 2.18
NM_001512.2 GSTA4 glutathione S-transferase A4 1.84 2.45 NM_002061.2 GCLM glutamate-cysteine ligase 1.59 2.06
NM_020299.3 AKR1B10 aldo-keto reductase family 1 1.83 2.42 NM_019007.3 ARMCX6 armadillo repeat
containing, X-linked 6
1.58 1.81
NM_016143.3 NSFL1C NSFL1 (p97) cofactor (p47) 1.83 2.61 NM_015974.2 CRYL1 crystallin, lambda 1 1.58 1.51
NM_080655.1 C9orf30 chromosome 9 open
reading frame 30
1.83 1.77 NM_006149.2 LGALS4 lectin 1.58 3.12
NM_001018109.1 PIR pirin 1.83 2.67 NM_012233.1 RAB3GAP1 RAB3 GTPase activating
protein subunit 1
1.57 1.78
NR_002200.1 FTHL2 ferritin, heavy polypeptide-
like 2 on chromosome 1
1.83 1.62 NM_002808.3 PSMD2 proteasome (prosome,
macropain) 26S subunit
1.57 1.72
NM_005485.3 PARP3 poly (ADP-ribose) polymerase
family
1.82 1.77 NM_001030001.1 RPS29 ribosomal protein S29 1.57 1.61
NM_058172.3 ANTXR2 anthrax toxin receptor 2 1.82 1.88 NM_052849.2 CCDC32 coiled-coil domain
containing 32
1.57 1.55
NR_002166.1 SEDLP spondyloepiphyseal
dysplasia, late, pseudogene
1.81 1.88 NM_015484.4 SYF2 SYF2 homolog 1.57 1.64
NM_022449.1 RAB17 member RAS oncogene
family
1.80 1.64 NM_001093771.1 TXNRD1 thioredoxin reductase 1 1.57 1.54
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Cip1
(CDKN1A) and p15
Ink4B (CDKN2B), which were up-regulated
by 5.2- and 3.1- fold, 24 hr after GANT61 administration
(Table 3). Additional genes required for the G1/S transition that
were down-regulated include the E2 transcription factor E2F2
(-4.2-fold), and other critical genes that were down-regulated by
2.1- to 3.2- fold, include CYCLIN E (CCNE2), CDK2 and
CDC25A. At G2/M, GANT61 induced down-regulated expres-
sion of CCNA2 (CYCLIN A2), CYCLIN B1 (CCNB1), CYCLIN
B2 (CCNB2), CDK1 (CDC2), and CDC25C by 2.3- to 3.1- fold
(Table 3).
To determine the robustness of cDNA microarray gene
expression profiling following treatment of HT29 and GC3/c1
cells with GANT61 (20 mM) for 24 hr, qRT-PCR was employed
to determine changes in expression of the selected group of 10
DEGs determined from the cDNA microarrays. The genes
involved and primers synthesized are shown in Table 4. qRT-
PCR was performed on cDNA generated using total RNA
independently isolated from GANT61-treated HT29 and GC3/c1
cells for 0 hr, 16 hr, 24 hr, 38 hr and 48 hr after treatment.
GAPDH was used to normalize all qRT-PCR data. Genes
determined by qRT-PCR included the expression of E2F2,
CCNE2, CDC25A and CDK2 at G1/S, which were down-
regulated, up-regulation of CDKN1A and CDKN2B at G1/S,
and down-regulation of CCNA2, CDC25C, CCNB2, and CDK1
at G2/M (Figure 5). The up-regulated or down-regulated changes
ACCESSION
NUMBER
GENE
SYMBOL DEFINITION Fold Change
ACCESSION
NUMBER
GENE
SYMBOL DEFINITION Fold Change
HT29 GC3/c1 HT29 GC3/c1
NM_198310.2 TTC8 tetratricopeptide repeat
domain 8
1.80 1.83 NM_017707.2 ASAP3 ArfGAP with SH3 domain,
ankyrin repeat and PH
domain 3
1.57 1.59
NM_002786.2 PSMA1 proteasome (prosome,
macropain) subunit
1.79 2.54 NM_020412.3 CHMP1B chromatin modifying
protein 1B
1.56 1.83
NM_002796.2 PSMB4 proteasome (prosome,
macropain) subunit
1.78 1.53 NM_017549.3 EPDR1 ependymin related protein 1 1.56 1.52
NR_002201.1 FTHL3P ferritin 1.78 2.10 NM_001080493.2 ZNF823 zinc finger protein 823 1.56 1.56
NM_020225.1 STOX2 storkhead box 2 1.78 5.98 NM_001008738.2 FNIP1 folliculin interacting protein 1 1.56 1.50
NM_080725.1 SRXN1 sulfiredoxin 1 homolog 1.78 1.67 NM_006343.2 MERTK c-mer proto-oncogene
tyrosine kinase
1.56 2.12
NM_015946.4 PELO pelota homolog 1.77 1.58 NM_014851.2 KLHL21 kelch-like 21 1.56 2.02
NM_020751.1 COG6 component of oligomeric
golgi complex 6
1.77 1.60 NM_002803.2 PSMC2 proteasome 1.55 1.77
NM_001080538.1 LOC441282 similar to aldo-keto
reductase family 1
1.77 2.31 NM_145918.2 CTSL1 cathepsin L1 1.55 1.96
NM_004487.3 GOLGB1 golgin B1 1.76 1.82 NM_003846.1 PEX11B peroxisomal biogenesis
factor 11 beta
1.55 1.92
NM_145040.2 PRKCDBP protein kinase C 1.76 3.27 NM_014905.2 GLS glutaminase 1.55 2.21
NM_201557.2 FHL2 four and a half LIM
domains 2
1.76 1.74 NM_016154.3 RAB4B member RAS oncogene family 1.55 2.22
NM_015037.2 KIAA0913 KIAA0913 1.75 1.52 NM_052901.2 SLC25A25 solute carrier family 25 1.54 1.55
NM_003003.2 SEC14L1 SEC14-like 1 1.74 1.94 NM_033212.2 CCDC102A coiled-coil domain containing
102A
1.54 1.75
NM_001031835.1 PHKB phosphorylase kinase 1.74 1.63 NM_002799.2 PSMB7 proteasome (prosome,
macropain) subunit
1.54 1.56
NM_016470.6 C20orf111 chromosome 20 open
reading frame 111
1.74 1.54 NM_001031716.1 OBFC2A oligonucleotide/oligosaccharide-
binding fold containing 2A
1.53 1.60
NM_001080791.1 C15orf57 chromosome 15 open
reading frame 57
1.74 1.63 NM_015187.3 KIAA0746 KIAA0746 protein 1.53 1.62
NM_002541.2 OGDH oxoglutarate (alpha-
ketoglutarate) dehydrogenase
1.74 1.55 NM_004034.1 ANXA7 annexin A7 1.52 1.75
NM_015922.1 NSDHL NAD(P) dependent steroid
dehydrogenase-like
1.74 2.30 NM_002815.2 PSMD11 proteasome (prosome,
macropain) 26S subunit
1.52 1.71
XM_001128220.1 PLEKHM1 pleckstrin homology
domain containing,
family M member 1
1.73 1.73 NM_014889.2 PITRM1 pitrilysin metallopeptidase 1 1.52 2.15
NM_004417.2 DUSP1 dual specificity phosphatase 1 1.73 1.78 NM_007126.2 VCP valosin-containing protein 1.51 1.79
NM_003971.3 SPAG9 sperm associated antigen 9 1.73 1.80 NM_032017.1 STK40 serine/threonine kinase 40 1.50 1.66
NM_016026.2 RDH11 retinol dehydrogenase 11 1.72 1.67 NM_032776.1 JMJD1C jumonji domain containing 1C 1.50 1.81
doi:10.1371/journal.pone.0013054.t001
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NM_015086.1 DDN dendrin 26.81 22.37 NM_014791.2 MELK maternal embryonic
leucine zipper kinase
22.50 22.09
NM_001013653.2 LRRC26 leucine rich repeat
containing 26
24.77 22.23 NM_016343.3 CENPF centromere protein
F, 350/400ka
22.50 22.71
NM_004091.2 E2F2 E2F transcription factor 2 24.23 22.26 NM_001789.2 CDC25A cell division cycle 25
homolog A
22.50 22.45
NM_182687.1 PKMYT1 protein kinase, membrane
associated tyrosine/
threonine 1
24.17 24.81 NM_024037.1 C1orf135 chromosome 1 open
reading frame 135
22.49 22.12
NM_001013653.1 LOC389816 cytokeratin associated
protein
23.85 22.32 NM_017669.2 ERCC6L excision repair cross-
complementing rodent
repair deficiency
22.48 23.22
NM_020675.3 SPC25 NDC80 kinetochore
complex component,
homolog
23.51 27.19 NM_031965.2 GSG2 germ cell associated 2
(haspin)
-2.47 22.79
NM_005733.1 KIF20A kinesin family member 20A 23.45 22.21 NM_018186.2 C1orf112 chromosome 1 open
reading frame 112
22.47 21.88
NM_002263.2 KIFC1 kinesin family member C1 23.36 22.74 NM_001786.2 CDC2 cell division cycle 2,
G1 to S and G2 to M
22.47 22.63
NM_006681.1 NMU neuromedin U 23.33 23.15 NM_002105.2 H2AFX H2A histone family,
member X
22.46 22.86
NM_014783.2 ARHGAP11A Rho GTPase activating
protein 11A
23.33 23.46 NM_018492.2 PBK PDZ binding kinase 22.46 22.21
NM_006176.1 NRGN neurogranin 23.29 24.20 NM_198516.1 GALNTL4 UDP-N-acetyl-alpha-D-
galactosamine
22.46 21.82
NM_016095.1 GINS2 GINS complex subunit 2 23.25 24.51 NM_018685.2 ANLN anillin, actin binding
protein
22.46 22.44
NM_018063.3 HELLS helicase, lymphoid-specific 23.24 23.42 NM_002915.3 RFC3 replication factor C
(activator 1) 3, 38kDa
22.45 22.59
NM_057735.1 CCNE2 cyclin E2 23.22 23.24 NM_007370.3 RFC5 replication factor C
(activator 1) 5, 36.5kDa
22.43 22.28
NM_014750.3 DLG7 discs, large homolog 7 23.21 22.48 NM_001032290.1 PSRC1 proline/serine-rich
coiled-coil 1
22.43 22.53
NM_001168.2 BIRC5 baculoviral IAP repeat-
containing 5
23.18 22.79 NM_000057.2 BLM Bloom syndrome 22.43 23.28
NM_001255.2 CDC20 cell division cycle 20
homolog
23.12 22.46 NM_012484.1 HMMR hyaluronan-mediated
motility receptor
22.43 21.82
NM_001237.2 CCNA2 cyclin A2 23.11 23.01 NM_145701.1 CDCA4 cell division cycle
associated 4
22.43 22.26
NM_144508.3 CASC5 cancer susceptibility
candidate 5
23.09 22.13 NM_024339.2 THOC6 THO complex 6 homolog 22.41 21.74
NM_017611.2 SLC43A3 solute carrier family 43,
member 3
23.05 22.60 NM_003258.2 TK1 thymidine kinase 1 22.41 23.74
NM_018154.2 ASF1B ASF1 anti-silencing
function 1 homolog B
23.03 23.06 NM_182776.1 MCM7 minichromosome
maintenance complex
component 7
22.39 22.54
NM_018410.3 HJURP Holliday junction
recognition protein
23.02 23.18 NM_178448.2 C9orf140 chromosome 9 open
reading frame 140
22.39 22.34
NM_004217.2 AURKB aurora kinase B 23.01 23.19 NM_001067.2 TOP2A topoisomerase (DNA) II
alpha 170kDa
22.39 23.16
NM_002692.2 POLE2 polymerase (DNA directed),
epsilon 2 (p59 subunit)
23.01 23.00 NM_178014.2 TUBB tubulin, beta 22.37 22.27
NM_018101.2 CDCA8 cell division cycle
associated 8
22.97 22.85 NM_018193.2 FANCI Fanconi anemia,
complementation group I
22.37 22.52
NM_002875.2 RAD51 RAD51 homolog 22.95 22.66 NM_206833.2 CTXN1 cortexin 1 22.36 22.04
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NM_031299.3 CDCA3 cell division cycle
associated 3
22.94 22.82 NM_031966.2 CCNB1 cyclin B1 22.36 22.28
NM_181803.1 UBE2C ubiquitin-conjugating
enzyme E2C
22.91 22.80 NM_005483.2 CHAF1A chromatin assembly
factor 1, subunit A (p150)
22.36 22.21
NM_001100118.1 XRCC3 X-ray repair
complementing
defective repair 3
22.90 23.66 NM_005518.2 HMGCS2 3-hydroxy-3-
methylglutaryl-Coenzyme
A synthase 2
22.35 22.88
NM_025049.2 PIF1 PIF1 59-to-39 DNA
helicase homolog
22.90 22.87 NM_019013.1 FAM64A family with sequence
similarity 64
22.35 23.13
NM_030928.2 CDT1 chromatin licensing and
DNA replication factor 1
22.86 22.76 NM_002129.2 HMGB2 high-mobility group
box 2
22.35 22.18
NM_016556.1 PSMC3IP PSMC3 interacting protein 22.85 23.47 NM_001034194.1 EXOSC9 exosome component 9 22.34 21.69
NM_182746.1 MCM4 minichromosome
maintenance complex
component 4
22.84 22.97 NM_031423.3 NUF2 NDC80 kinetochore
complex component,
homolog
22.34 22.48
NM_016937.2 POLA1 polymerase (DNA directed),
alpha 1, catalytic subunit
22.84 22.19 NM_002916.3 RFC4 replication factor C
(activator 1) 4, 37kDa
22.33 22.36
NM_007086.2 WDHD1 WD repeat and HMG-box
DNA binding protein 1
22.80 22.53 NM_004111.4 FEN1 flap structure-specific
endonuclease 1
22.33 21.97
NM_001761.1 CCNF cyclin F 22.80 22.77 NM_145061.3 C13orf3 chromosome 13 open
reading frame 3
22.33 22.53
NM_012177.2 FBXO5 F-box protein 5 22.78 22.95 NM_001012413.1 SGOL1 shugoshin-like 1 22.33 22.85
NM_018518.3 MCM10 minichromosome
maintenance complex
component 10
22.78 24.01 NM_207418.2 GCUD2 gastric cancer up-
regulated-2
22.32 22.28
NM_003579.2 RAD54L RAD54-like 22.76 22.98 NM_199413.1 PRC1 protein regulator of
cytokinesis 1
22.32 22.13
NM_020242.1 KIF15 kinesin family member 15 22.75 23.00 NM_006461.3 SPAG5 sperm associated
antigen 5
22.31 21.92
NM_004336.2 BUB1 BUB1 budding uninhibited
by benzimidazoles 1
homolog
22.74 22.47 NM_080668.2 CDCA5 cell division cycle
associated 5
22.29 22.94
NM_003384.2 VRK1 vaccinia related kinase 1 22.73 21.89 NM_006101.1 NDC80 NDC80 homolog 22.29 23.12
NM_018454.5 NUSAP1 nucleolar and spindle
associated protein 1
22.72 22.40 NM_001012507.1 C6orf173 chromosome 6 open
reading frame 173
22.29 22.38
NM_001034.1 RRM2 ribonucleotide reductase
M2 polypeptide
22.72 22.54 NM_002497.2 NEK2 NIMA (never in mitosis
gene a)-related kinase 2
22.29 22.10
NM_012112.4 TPX2 microtubule-associated,
homolog
22.72 22.32 NM_024900.3 PHF17 PHD finger protein 17 22.28 21.67
NM_152259.3 C15orf42 chromosome 15 open
reading frame 42
22.70 23.44 NM_001040668.1 BCL2L12 BCL2-like 12 22.28 21.93
NM_001042426.1 CENPA centromere protein A 22.70 23.28 NM_014264.3 PLK4 polo-like kinase 4 22.27 21.97
NM_012415.2 RAD54B RAD54 homolog B 22.69 21.88 NM_022809.2 CDC25C cell division cycle 25
homolog C
22.27 22.05
NM_181471.1 RFC2 replication factor C
(activator 1) 2, 40kDa
22.69 22.50 NM_152515.2 CKAP2L cytoskeleton
associated protein 2-like
22.26 22.29
NM_005480.2 TROAP trophinin associated
protein
22.69 22.49 NM_006026.2 H1FX H1 histone family,
member X
22.24 22.08
NM_006845.2 KIF2C kinesin family member 2C 22.68 22.81 NM_003276.1 TMPO thymopoietin 22.24 21.95
NM_022346.3 NCAPG non-SMC condensin I
complex
22.68 22.70 NM_018136.3 ASPM asp (abnormal spindle)
homolog
22.23 22.51
NM_004260.2 RECQL4 RecQ protein-like 4 22.68 23.00 NM_016426.4 GTSE1 G-2 and S-phase
expressed 1
22.23 22.44
NM_003318.3 TTK TTK protein kinase 22.67 22.40 NM_014875.1 KIF14 kinesin family member 14 22.23 22.12
NM_030919.2 FAM83D family with sequence
similarity 83, member D
22.66 22.08 NM_014109.2 ATAD2 ATPase family, AAA
domain containing 2
22.23 22.21
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NM_001254.3 CDC6 cell division cycle 6
homolog
22.66 23.05 NM_003390.2 WEE1 WEE1 homolog 22.22 21.97
NM_001034836.1 RDM1 RAD52 motif 1 22.65 22.65 NM_002388.3 MCM3 minichromosome
maintenance complex
component 3
22.22 22.45
NM_004526.2 MCM2 minichromosome
maintenance complex
component 2
22.65 23.43 NM_005030.3 PLK1 polo-like kinase 1 22.22 22.37
NM_004701.2 CCNB2 cyclin B2 22.65 22.52 NM_005375.2 MYB v-myb myeloblastosis
viral oncogene homolog
22.22 22.01
NM_032818.2 C9orf100 chromosome 9 open
reading frame 100
22.64 22.30 NM_024789.3 TMEM180 transmembrane
protein 180
22.20 21.63
NM_006397.2 RNASEH2A ribonuclease H2,
subunit A
22.64 22.52 NM_001012716.1 C18orf56 chromosome 18 open
reading frame 56
22.20 22.30
NM_014736.4 KIAA0101 KIAA0101 22.61 23.47 NM_017760.5 NCAPG2 non-SMC condensin II
complex, subunit G2
22.20 22.11
NM_004219.2 PTTG1 pituitary tumor-
transforming 1
22.61 22.23 NM_005192.2 CDKN3 cyclin-dependent kinase
inhibitor 3
22.20 21.98
NM_182513.1 SPC24 SPC24, NDC80
kinetochore complex
component, homolog
22.61 23.15 NM_006231.2 POLE polymerase (DNA
directed)
22.19 23.53
NM_198948.1 NUDT1 nudix (nucleoside
diphosphate linked
moiety X)-type motif 1
22.59 23.09 NM_018124.3 RFWD3 ring finger and WD
repeat domain 3
22.19 21.56
NM_033286.2 C15orf23 chromosome 15 open
reading frame 23
22.58 21.77 NM_006088.5 TUBB2C tubulin, beta 2C 22.19 21.63
NM_024053.3 CENPM centromere protein M 22.57 23.45 NM_198434.1 AURKA aurora kinase A 22.18 21.68
NM_006479.3 RAD51AP1 RAD51 associated
protein 1
22.57 22.54 NM_007280.1 OIP5 Opa interacting
protein 5
22.18 22.34
NM_006739.3 MCM5 minichromosome
maintenance complex
component 5
22.56 23.21 NM_014176.2 UBE2T ubiquitin-conjugating
enzyme E2T (putative).
22.15 22.01
NM_203401.1 STMN1 stathmin
1/oncoprotein 18
22.56 22.32 NM_199420.3 POLQ polymerase (DNA
directed), theta
22.14 22.45
NM_013277.2 RACGAP1 Rac GTPase
activating protein 1
22.55 21.79 NM_001211.4 BUB1B BUB1 budding
uninhibited by
benzimidazoles 1 homolog
beta
22.13 22.23
NM_001005413.1 ZWINT ZW10 interactor 22.55 22.64 NM_001025248.1 DUT deoxyuridine
triphosphatase
22.13 22.36
NM_004856.4 KIF23 kinesin family member 23 22.54 22.17 NM_031217.2 KIF18A kinesin family member
18A
22.13 21.99
NM_004523.2 KIF11 kinesin family member 11 22.53 22.12 NM_025108.2 C16orf59 chromosome 16 open
reading frame 59
22.12 23.48
NR_002734.1 PTTG3 pituitary tumor-
transforming 3
22.53 22.43 NM_001042517.1 DIAPH3 diaphanous homolog 3 22.12 22.34
NM_006027.3 EXO1 exonuclease 1 22.52 23.86 NM_017998.1 C9orf40 chromosome 9 open
reading frame 40
22.11 21.85
NM_016448.1 DTL denticleless homolog 22.51 23.12 NM_052844.3 WDR34 WD repeat domain 34 22.11 22.71
NM_022770.2 GINS3 GINS complex subunit 3
(Psf3 homolog)
22.10 21.65 NM_017918.3 CCDC109B coiled-coil domain
containing 109B
21.84 21.84
NM_003503.2 CDC7 cell division cycle 7
homolog
22.09 21.97 NM_005782.2 THOC4 THO complex 4 21.84 21.63
NM_001071.1 TYMS thymidylate synthetase 22.08 23.41 NM_003035.2 STIL SCL/TAL1 interrupting
locus
21.84 21.95
NM_005441.2 CHAF1B chromatin assembly
factor 1, subunit B (p60)
22.08 22.25 NM_005342.2 HMGB3 high-mobility group
box 3
21.83 21.60
NM_014865.2 NCAPD2 non-SMC condensin I
complex, subunit D2
22.07 22.03 NM_018132.3 CENPQ centromere protein Q 21.83 22.10
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NM_001798.2 CDK2 cyclin-dependent
kinase 2
22.07 21.88 NM_024516.2 C16orf53 chromosome 16 open
reading frame 53
21.81 21.86
NM_022720.5 DGCR8 DiGeorge syndrome
critical region gene 8
22.07 21.57 NM_015895.3 GMNN geminin, DNA
replication inhibitor
21.81 21.87
NM_145018.2 C11orf82 chromosome 11 open
reading frame 82
22.06 22.28 NM_002689.2 POLA2 polymerase (DNA
directed), alpha 2 (70kD
subunit)
21.81 22.11
NM_016195.2 KIF20B kinesin family member 20B 22.06 21.63 NM_000154.1 GALK1 galactokinase 1 21.80 21.84
NM_001008393.1 LOC201725 hypothetical protein 22.05 21.98 NM_004499.3 HNRNPAB heterogeneous nuclear
ribonucleoprotein A/B
21.80 22.31
NM_000465.1 BARD1 BRCA1 associated RING
domain 1
22.05 22.42 NM_024656.2 GLT25D1 glycosyltransferase 25
domain containing 1
21.80 21.62
NM_003173.2 SUV39H1 suppressor of
variegation 3-9 homolog 1
22.05 21.89 NM_199250.1 C19orf48 chromosome 19 open
reading frame 48
21.79 21.83
NM_015426.2 WDR51A WD repeat domain 51A 22.05 21.60 NM_153329.2 ALDH16A1 aldehyde dehydrogenase
16 family, member A1
21.79 21.98
NM_020342.1 SLC39A10 solute carrier family 39 22.05 23.15 NM_032637.2 SKP2 S-phase kinase-associated
protein 2 (p45)
21.79 22.00
NM_144999.2 LRRC45 leucine rich repeat
containing 45
22.04 23.33 NM_006191.2 PA2G4 proliferation-associated
2G4, 38kDa
21.78 21.84
NM_000946.2 PRIM1 primase, DNA,
polypeptide 1 (49kDa)
22.04 22.29 NM_001033580.1 MYO19 myosin XIX 21.78 23.61
NM_016183.3 MRTO4 turnover 4 homolog 22.04 21.68 NM_017915.2 C12orf48 chromosome 12 open
reading frame 48
21.78 21.92
NM_017518.5 UCHL5IP UCHL5 interacting protein 22.04 21.75 NM_003362.2 UNG uracil-DNA glycosylase 21.76 21.55
NM_020394.2 ZNF695 zinc finger protein 695 22.03 22.78 NM_014985.2 CEP152 centrosomal protein
152kDa
21.75 22.37
NM_203394.2 E2F7 E2F transcription factor 7 22.02 22.03 NM_001333.2 CTSL2 cathepsin L2 21.75 21.70
NM_173529.3 C18orf54 chromosome 18 open
reading frame 54
22.02 21.99 NM_016310.2 POLR3K polymerase (RNA) III (DNA
directed) polypeptide K,
12.3 kDa
21.75 21.59
NM_000156.4 GAMT guanidinoacetate N-
methyltransferase
22.02 21.64 NM_006406.1 PRDX4 peroxiredoxin 4 21.74 21.93
NM_007299.2 BRCA1 breast cancer 1, early
onset
22.02 22.11 NM_005484.2 PARP2 poly (ADP-ribose)
polymerase family,
member 2
21.74 21.53
NM_014641.1 MDC1 mediator of DNA
damage checkpoint 1
22.01 21.57 NM_001039091.1 PRPS2 phosphoribosyl
pyrophosphate
synthetase 2
21.73 21.60
NM_032485.4 MCM8 minichromosome
maintenance complex
component 8
22.01 23.18 NM_015703.3 RRP7A ribosomal RNA
processing 7 homolog A
21.73 21.71
NM_024660.2 TMEM149 transmembrane
protein 149
22.01 22.07 NM_015032.1 PDS5B PDS5, regulator of
cohesion maintenance,
homolog B
21.73 21.78
NM_015414.2 RPL36 ribosomal protein L36 22.00 22.40 NM_000992.2 RPL29 ribosomal protein L29 21.73 22.53
NM_021734.3 SLC25A19 solute carrier family 25,
member 19
22.00 21.67 NM_173608.1 C14orf80 chromosome 14 open
reading frame 80
21.72 21.73
NM_003504.3 CDC45L CDC45 cell division
cycle 45-like
22.00 22.84 NM_001042550.1 SMC2 structural maintenance of
chromosomes 2
21.72 21.92
NM_014708.3 KNTC1 kinetochore associated 1 21.99 21.86 NM_014285.4 EXOSC2 exosome component 2 21.72 21.70
NM_018131.3 CEP55 centrosomal protein
55kDa
21.98 22.01 NM_138961.1 ESAM endothelial cell adhesion
molecule
21.71 22.21
NM_007243.1 NRM nurim 21.98 22.22 NM_145159.1 JAG2 jagged 2 21.70 21.89
NM_003517.2 HIST2H2AC histone cluster 2, H2ac 21.98 22.54 NM_006392.2 NOL5A nucleolar protein 5A
(56kDa with KKE/D repeat)
21.69 21.70
NM_001002800.1 SMC4 structural maintenance
of chromosomes 4
21.98 21.94 NM_033661.3 WDR4 WD repeat domain 4 21.69 21.84
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NM_001033505.1 CSTF3 cleavage stimulation factor,
39 pre-RNA, subunit 3, 77kD
21.97 21.96 NM_032358.2 CCDC77 coiled-coil domain
containing 77
21.68 21.54
NM_181716.2 PRR6 proline rich 6 21.96 21.85 NM_018693.2 FBXO11 F-box protein 11 21.68 21.93
NM_018663.1 PXMP2 peroxisomal membrane
protein 2, 22kDa
21.96 22.02 NM_001026.3 RPS24 ribosomal protein S24 21.68 21.94
NM_005915.4 MCM6 minichromosome
maintenance complex
component 6
21.96 22.25 NM_016292.1 TRAP1 TNF receptor-associated
protein 1
21.67 21.51
NM_005189.1 CBX2 chromobox homolog 2 21.96 21.68 NM_017613.2 DONSON downstream neighbor of
SON
21.66 21.61
NM_001379.1 DNMT1 DNA (cytosine-5-)-
methyltransferase 1
21.96 21.84 NM_006047.4 RBM12 RNA binding motif
protein 12
21.66 21.91
NM_001002018.1 HCFC1R1 host cell factor C1 regulator
1 (XPO1 dependent)
21.96 21.79 NM_012140.3 SLC25A10 solute carrier family 25
(dicarboxylate transporter),
member 10
21.66 21.55
NM_000234.1 LIG1 ligase I, DNA, ATP-
dependent
21.96 22.81 NM_001025238.1 TSPAN4 tetraspanin 4 21.66 21.94
NM_138443.2 CCDC5 coiled-coil domain
containing 5 (spindle
associated)
21.95 21.68 NM_001008735.1 HMG1L1 high-mobility group
(nonhistone chromosomal)
protein 1-like 1
21.66 21.62
NM_020315.4 PDXP pyridoxal (pyridoxine,
vitamin B6) phosphatase
21.95 22.04 NM_005956.2 MTHFD1 methylenetetrahydrofolate
dehydrogenase
(NADP+dependent) 1
21.65 21.69
NM_032117.2 MND1 meiotic nuclear divisions 1
homolog
21.95 22.63 NM_145014.1 HYLS1 hydrolethalus
syndrome 1
21.65 21.62
NM_194255.1 SLC19A1 solute carrier family 19
(folate transporter),
member 1
21.95 21.93 NM_004309.3 ARHGDIA Rho GDP dissociation
inhibitor (GDI) alpha
21.64 21.75
NM_058216.1 RAD51C RAD51 homolog C 21.94 22.13 NM_182649.1 PCNA proliferating cell nuclear
antigen
21.63 21.99
NM_018725.3 IL17RB interleukin 17 receptor B 21.94 22.25 NM_032118.2 WDR54 WD repeat domain 54 21.63 21.77
NM_024844.3 NUP85 nucleoporin 85kDa 21.93 21.53 NM_015697.6 COQ2 coenzyme Q2 homolog 21.63 21.85
NM_015190.3 DNAJC9 DnaJ (Hsp40) homolog,
subfamily C, member 9
21.93 21.64 NM_032982.2 CASP2 caspase 2 21.63 21.67
NM_004237.2 TRIP13 thyroid hormone
receptor interactor 13
21.93 22.23 NM_001042762.1 FIGNL1 fidgetin-like 1 21.63 21.85
NM_000179.1 MSH6 mutS homolog 6 21.93 21.83 NM_001100417.1 UBR7 ubiquitin protein ligase E3
component n-recognin 7
(putative)
21.61 21.64
NM_001009936.1 PHF19 PHD finger protein 19 21.93 22.42 NM_003146.2 SSRP1 structure specific
recognition protein 1
21.60 21.66
NM_003609.2 HIRIP3 HIRA interacting protein 3 21.92 22.01 NM_152308.1 C16orf75 chromosome 16 open
reading frame 75
21.60 21.99
NM_022145.3 CENPK centromere protein K 21.92 22.25 NM_001024662.1 RPL6 ribosomal protein L6 21.60 21.56
NM_022908.1 NT5DC2 59-nucleotidase domain
containing 2
21.92 21.81 NM_182620.3 FAM33A family with sequence
similarity 33, member A
21.59 22.17
NM_006342.1 TACC3 transforming, acidic coiled-
coil containing protein 3
21.92 22.27 NM_033120.2 NKD2 naked cuticle homolog 2 21.59 21.65
NM_001080450.1 KIAA1553 KIAA1553 21.92 21.65 NM_003472.2 DEK DEK oncogene (DNA
binding)
21.58 21.91
NM_001018115.1 FANCD2 Fanconi anemia,
complementation group D2
21.92 22.39 NM_032015.3 RNF26 ring finger protein 26 21.58 21.70
NM_001033.2 RRM1 ribonucleotide reductase M1
polypeptide
21.92 21.87 NM_018455.3 CENPN centromere protein N 21.57 22.01
NM_001078174.1 SLC29A1 solute carrier family 29
(nucleoside transporters)
21.91 22.19 NM_003091.3 SNRPB small nuclear
ribonucleoprotein
polypeptides B and B1
21.56 21.52
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by cDNA microarray profiling, were confirmed by qRT-PCR
(Figure 5).
Discussion
The HH signaling pathway is activated in a variety of human
cancers following mutations in genes that regulate canonical HH
signaling, including the receptor PTC, and the HH signaling
molecule, SMO, and can also be activated via transcriptional up-
regulation of the HH ligands (reviewed in [3]). This pathway is
becoming of increasing importance due to gaining insight into its
prominent role in many developmental processes, and in the
maintenance of the malignant phenotype in a wide variety of
human cancers, whose growth has been found to be prevented by
selective inhibition of constitutive HH pathway activity [14,35,36].
Tumors of the brain, prostate, skin, pancreas, and kidney have
demonstrated the requirement for HH-GLI signaling, and have
responded to inhibition of the HH signaling target molecule SMO
by cyclopamine or SMOshRNA [4,19,20,21,22,23].
The transcriptional activators in HH signaling comprise
members of the GLI family of transcription factors, GLI1 and
GLI2, which have both distinct as well as overlapping functions
[16]. Activation of the GLI proteins is an intricate process that
involves modifications and interactions of a number of positive and
negative pathway regulators and is not fully understood [1,14,35].
Target genes regulated by the HH signaling pathway differ
between tissues and cell types, as well as being influenced by the
presence or absence of regulatory factors co-expressed with GLI
proteins that eventually determine the transcriptional programs
activated by HH signaling [6,37]. Thus, oncogenic signaling
pathways converge on canonical HH signaling at the level of the
GLI transcription factors and additionally on target genes
downstream of GLI1 and GLI2 to further drive the HH signaling
pathway in cellular survival in malignancies [6,7,20,38,39,40].
The HH signaling phenotype is therefore significantly influenced
and ultimately determined by the co-expression of additional
regulatory factors, and hence by the cellular context of gene
expression.
HH signaling plays a role in the differentiation program of
normal intestinal villi [11,12,41], and it has been suggested
recently that human colon cancer epithelial cells display a HH-
GLI signaling axis in the process of carcinogenesis [24,25].
Expression of HH-GLI pathway components was consistently
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NM_153485.1 NUP155 nucleoporin 155kDa 21.91 21.65 NM_003863.2 DPM2 dolichyl-phosphate
mannosyltransferase
polypeptide 2
21.56 21.77
NM_002482.2 NASP nuclear autoantigenic
sperm protein (histone-
binding)
21.91 21.96 NM_017916.1 PIH1D1 PIH1 domain
containing 1
21.55 21.97
NM_176880.4 NR2C2AP nuclear receptor 2C2-
associated protein
21.90 21.87 NM_020810.1 TRMT5 tRNA methyltransferase
5 homolog
21.55 21.54
NM_021953.2 FOXM1 forkhead box M1 21.90 22.28 NM_058219.2 EXOSC6 exosome component 6 21.55 21.65
NM_015721.2 GEMIN4 gem (nuclear organelle)
associated protein 4
21.90 21.54 NM_002882.2 RANBP1 RAN binding protein 1 21.54 21.88
NM_018188.2 ATAD3A ATPase family, AAA
domain containing 3A
21.89 21.70 NM_007111.3 TFDP1 transcription factor Dp-1 21.54 21.51
NM_145060.3 C18orf24 chromosome 18 open
reading frame 24
21.89 22.45 NM_021709.1 SIVA CD27-binding (Siva)
protein
21.54 21.71
NM_018365.1 MNS1 meiosis-specific nuclear
structural 1
21.89 22.12 NM_015140.2 TTLL12 tubulin tyrosine ligase-
like family, member 12
21.53 21.61
NM_012310.3 KIF4A kinesin family member 4A 21.89 22.38 NM_022044.2 SDF2L1 stromal cell-derived
factor 2-like 1
21.53 21.70
NM_015261.2 NCAPD3 non-SMC condensin II
complex, subunit D3
21.88 21.88 NM_002346.1 LY6E lymphocyte antigen 6
complex, locus E
21.52 21.56
NM_013296.3 GPSM2 G-protein signalling
modulator 2
21.87 21.63 NM_022490.1 POLR1E polymerase (RNA) I
polypeptide E, 53kDa
21.52 21.77
NM_002691.1 POLD1 polymerase (DNA directed),
delta 1, catalytic subunit
21.87 22.22 NM_032799.4 ZDHHC12 zinc finger, DHHC-type
containing 12
21.51 21.64
NM_203467.1 PPIL5 peptidylprolyl isomerase
(cyclophilin)-like 5
21.87 21.79 NM_001017980.2 LOC203547 hypothetical protein 21.51 21.54
NM_015201.3 BOP1 block of proliferation 1 21.87 22.29 NM_003801.3 GPAA1 glycosylphosphatidylinositol
anchor attachment
protein 1 homolog
21.51 21.89
NM_018353.3 C14orf106 chromosome 14 open
reading frame 106
21.86 21.54 NM_016594.1 FKBP11 FK506 binding protein 11,
19 kDa
21.50 21.94
NM_080626.5 BRI3BP BRI3 binding protein 21.84 21.72 NM_022754.4 SFXN1 sideroflexin 1 21.50 21.88
doi:10.1371/journal.pone.0013054.t002
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carcinomas and tumors metastatic to the liver [26], consistent
with findings of previous investigators [25,42,43]. Thus, using
qRT-PCR, the expression of GLI1, PTCH1, GLI2 and SHH was
determined in all human colon carcinomas examined. The
requirement for both GLI1 and GLI2 for sustained proliferation
and survival of human colon carcinoma cell lines in vitro,
including HT29, was demonstrated using siRNA technology [26].
In addition, knockdown of SMO by SMOshRNA prevented the
growth of HT29 cells in SCID mice, while wt HT29 subcutaneous
xenografts responded to cyclopamine by reduction in tumor
volume [26]. Thus, canonical activation of GLI1 and GLI2 via
SMO is important for the survival and proliferation of human
colon carcinoma cells in vivo.
In the current study, the function of both GLI1 and GLI2
downstream of SMO was inhibited in the presence of GANT61, a
small molecule inhibitor that was identified from a cell-based
screen to specifically inhibit GLI1-mediated transcription, but that
also inhibited the function of GLI2 [34]. This agent was selected to
specifically inhibit the final arbiters of HH signaling, the GLI
transcription factors, in elucidation of the downstream target genes
that determine HH-dependent proliferation in human colon
carcinoma cells. Two cell lines, well characterized in our
laboratories, HT29 and GC3/c1, were treated with GANT61
(20 mM) for 24 hr, and the expression of GLI1, GLI2 and PTCH1
mRNA was down-regulated. Further, the effects on cellular
proliferation as determined by the distribution of cells within the
cell cycle and flow cytometric analysis demonstrated accumulation
of cells in G1 following treatment, with a concomitant decrease of
cells from the G2/M compartment, and in the case of HT29, also
from S-phase, suggesting the induction of a G1/S checkpoint.
HT29 and GC3/c1 cells were subsequently treated with
GANT61 (20 mM) for 24 hr, RNA was extracted, and changes
in gene expression were determined by Illumina cDNA micro-
array profiling. Following statistical analyses, 1,368 genes in HT29
and 1,002 genes in GC3/c1, were determined to be significantly
modulated by GANT61 treatment (FC.1.5; p,0.001). For genes
that were up-regulated in expression, 296 genes were common to
both cell lines, and for down-regulated genes, 309 genes were
common to both cell lines. The blockade of cells at the G1/S
boundary is evidenced by up-regulated expression of p21
Cip1 and
p15
Ink4b that in part regulate the G1/S transition. p15
Ink4b is a
member of the Ink4 family of CDK inhibitors, is induced in
response to cytostatic signals [32,44], and complexes with
CYCLIN D/CDK4 or CYCLIN D/CDK6 to mediate G1-phase
arrest at the G1/S transition in certain systems [30,32]. p21
Cip1
can bind a broad range of cyclin-CDK complexes, with a
preference for those containing CDK2 (reviewed in [31,45], and
during a normal cell cycle, facilitates active cyclin-CDK complex
formation to promote cell proliferation. However when overex-
pressed, p21
Cip1 forms an inhibitory complex with CYCLIN E/
CDK2, leading to G1- and consequently S- phase arrest, thereby
forming the G1/S checkpoint [46,47]. The scheduled timing of
expression of CYCLINS E, A and B that drive cell cycle
progression, is reflected in the major changes in the phases of
the cell cycle. CYCLIN E is expressed at maximal levels in cells
undergoing the G1 to S transition, declining during S-phase
progression, such that G2/M cells are CYCLIN E-negative
(reviewed in [30]). CYCLIN A is expressed in late G1,
demonstrates pronounced expression during S-phase, and increas-
es as the cells advance towards G2, with degradation in early
mitosis; B type cyclins begin to be expressed in late S-phase, and
drive the cells though G2- and M- phases of the cell cycle [30].
CDK2 controls the G1/S transition by complexing with CYCLIN
E, and is activated by CDC25A, which dephosphorylates CDK2
[48]. CDC2 controls cellular entry into mitosis at the G2/M
transition, thereby forming complexes with CYCLINS A and B, is
activated by CDC25C, and is down-regulated in late M-phase
[29]. All of these genes are down-regulated in expression in
response to the inhibition of GLI1/GLI2 function (Table 2). Thus,
signals elicited to promote cellular accumulation at G1/S lead to
the repression of genes that regulate further cell cycle progression,
and p21
Cip1 expression has been shown to deplete the expression
of genes that regulate DNA replication and repair, and mitosis
[49,50,51]. In the current study these genes include CDC6 (active
at the G1/S transition and essential for the initiation of DNA
replication), TYMS, TOP2A, TK1, POLE and POLE2 (S-phase),
and AURKB and CDC20 (mitosis [52,53]), determined by heat
map analysis. A schematic representation of the genes involved in
GANT61-induced inhibition of cell cycle progression at G1/S, S-
phase progression, and regulation during G2- and M-phases,
identified from cDNA microarrays, heat map analysis, and by
qRT-PCR, is shown in Figure 6, and involves 5 of the 12 common
signaling pathways determined by IPA analysis.
Comprehensive cDNA microarray gene profiling analysis of
genes that determine the HH signaling phenotype has been
conducted only in non-cancer cell models. In these systems, GLI
activation has been stimulated by EGF treatment [6], stable GLI1
or HA-RAS expression [7], or expression of constitutively
activated GLI2 [16]. In these studies, CYCLIN D [6,7],
GADD153 [7], CDKN2B, CDKN1A, CDK2, PCNA, TOP2A,
CCNB1, XRCC1 [16], have been identified as genes activated
downstream of GLI. In GANT61-treated human colon carcinoma
cells, novel DNA damage-inducible transcripts DDIT3
(GADD153), DDIT4 (REDD1), DDIT2 (GADD45G), PPP1R-
15A (GADD34) and ATF3 were significantly up-regulated
concomitant with the arrest of cells at G1/S. TP53INP1, involved
in cell cycle regulation, and TP53INP2, linked to cell death
responses, were also up-regulated. Additional novel genes involved
in S-phase progression and DNA damage response that were
significantly down-regulated include KIAA0101 (p15[PAF]),
Replication Factor C variants 2, 3, 4, 5, CDT1, the E2F
transcription factors CDCA4 and TFDP1, MDC1, PCNA,
FANCD2, and the genes involved in DNA repair, RAD51C
(XRCC3), RAD54B, RAD51 and HELLS.
In summary, we have compared gene expression profiles in two
human colon carcinoma cell lines after targeting the function of
the transcriptional regulators of HH signaling, GLI1 and GLI2,
using the small molecule inhibitor GANT61. Data are consistent
with accumulation of cells at the G1/S boundary, as evidenced
from flow cytometric analysis, cDNA microarray gene profiling,
and qRT- PCR. GANT61-treated cells demonstrated up-regulat-
Figure 3. The top 15 canonical signaling pathways influenced by inhibition of GLI1/GLI2 function in HT29 and GC3/c1 cells. The top
15 canonical signaling pathways, determined by IPA, that were significantly up-regulated or down-regulated by GANT61 treatment in HT29 and GC3/
c1 cells, are shown. The 1,368 DEGs in HT29 and 1,002 DEGs in GC3/c1 were mapped to the IPA- defined network. The significance p-values that
determine the probability that the association between the genes in the dataset and the canonical pathway is by chance alone were calculated by
Fisher’s exact test, and are expressed as –log (p-value). A. Pathways with enriched down-regulated genes. B. Pathways with enriched up-regulated
genes. Blue: Pathways common to both HT29 and GC3/c1. Red: Pathways unique to either HT29 or GC3/c1. Yellow squares: Ratio of the number of
DEGs that map to a specific canonical pathway divided by total number of genes that make up that pathway.
doi:10.1371/journal.pone.0013054.g003
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PLoS ONE | www.plosone.org 17 October 2010 | Volume 5 | Issue 10 | e13054Figure 4. Heat map showing fold change patterns of most highly DEGs in GANT61-treated human colon carcinoma cell lines. The
heat map was generated in Matlab (Mathworks), and compares fold change patterns of the most highly DEGs in HT29 and GC3/c1 cells after GANT61
treatment. The most highly DEGs demonstrated a differential expression p-value of p,0.001 between vehicle control (0.2% DMSO) and GANT61-
treated cells. Left panel (red): up-regulated genes. Right panel (green): down-regulated genes. Genes denoted with asterisks define those genes with
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Cip1 and p15
Ink4b that
function at the G1/S boundary, and down-regulated expression of
additional key genes that determine the G1/S transition, initiation
of DNA replication, S-phase progression, DNA repair, and
subsequent transition through the G2/M phases. Inhibition of
the transcriptional regulation of HH signaling in human colon
carcinoma cells therefore directly involves genes that regulate cell
cycle transition through G1/S, cell cycle progression, and
proliferation, and genes involved in stress-induced and DNA
damage responses.
Materials and Methods
Human colon carcinoma cell lines
HT29 was purchased from ATCC (Manassas, VA), while GC3/
c1 was established in culture by our group from a human colon
adenocarcinoma xenograft model [54]; both cell lines express
mutant p53 alleles. Cell lines were maintained in the presence of
folate-free RPMI 1640 medium containing 10% dFBS and 80 nM
[6RS] 5-methyltetrahydrofolate.
Flow cytometric analysis
HT29 and GC3/c1 cells were plated at a density of 100,000
cells/well in six-well plates. After overnight attachment, cells were
treated with GANT61 (20mM; Enzo Life Sciences, Germany) or
vehicle control (DMSO, 0.2%), in duplicate, for 24 hr, followed by
washing 61 with PBS, trypsinization, and centrifugation. Cells
were fixed with 70% ethanol at RT, 20–30 min, stored at 220uC
overnight, centrifuged for 5 min at 2006g to remove ethanol, and
washed 61 in PBS. The cells were resuspended in PBS, and low
molecular weight DNA was extracted using DNA extraction buffer
(0.2M Na2HPO4 and 0.1M citric acid, pH 7.8) for 5 min. The
extracted DNA was centrifuged and resuspended in DNA staining
solution containing propidium iodide (50 mg) and DNAse-free
RNAse (2 mg), and allowed to incubate for 30 min in the dark at
RT. Distribution of cells throughout the cell cycle was analyzed
using a FACSCalibur flow cytometer, and data were analyzed
using CellQuest software.
RNA isolation
Cells were seeded at 7610
6 cells/10 cm plate overnight at
<60% confluency, and subsequently treated with either vehicle
control (0.2% DMSO) or GANT61 (20 mM), in duplicate, for
24 hr. Cells were subsequently harvested and RNA was isolated
using the RNeasyH Mini Kit (Qiagen, Valencia, CA) following the
manufacturer’s protocol. Integrity of the RNA was determined by
spectrophotometry and electrophoresis.
cDNA microarray analysis
RNA (250 ng) was reverse transcribed into cRNA and biotin-
UTP labeled using the IlluminaH TotalPrep RNA Amplification
Kit (Ambion, Applied Biosystems, Foster City, CA) according to
the manufacturer’s protocol. cRNA was quantified using a
nanodrop spectrophotometer, and the cRNA quality (size
distribution) further analyzed on a 1% agarose gel. Biotinylated
cRNAs were hybridized to the Illumina Human-ref8 V3.0
BeadChip (Illumina, San Diego, CA) that represents 18,401
genes, using standard protocols. The arrays were washed and
subsequently scanned using an Illumina BeadArray Reader.
Raw signal intensities of gene expression data were processed
and analyzed using GenomeStudio (Illumina), with background
subtraction and average normalization performed on the average
signal intensities, and p-values were calculated. Raw data were
exported from GenomeStudio into Excel (available as Data S1 and
Data S2), and the fold change in gene expression calculated, by
dividing the average gene expression signal intensity of treated
samples (GANT61) with that of the vehicle control (DSMO).
Differential gene expression (DEG) analysis between control and
GANT61-treated samples, was subsequently conducted using the
Illumina customer model, which applies multiple testing correc-
tions that determines the false discovery rate (FDR; [55]. Thus,
FDR-adjusted differential scores and p-values for each gene/probe
set between treated and control samples were generated. Genes
with a FDR-adjusted p-value of p,0.001 and fold change $1.5
were considered to be DEGs and were subjected to Venn analysis
and Ingenuity Pathway analysis.
specific roles in G1/S transition, S-phase progression, DNA replication or repair, or regulation of the G2- or M- phase transitions. Fold changes of all
down-regulated DEGs and all but one up-regulated DEG are #8 (central color spectrum bar).
doi:10.1371/journal.pone.0013054.g004
Table 3. Gene expression changes from cDNA arrays at G1/S and G2/M.
Cell Cycle Phase Accession NumberGene Symbol Gene Name Fold Change
HT29 GC3/c1
G1/S NM_000389.2 CDKN1A cyclin-dependent kinase inhibitor 1A (p21
Cip1) +5.21 +2.02
NM_078487.2 CDKN2B cyclin-dependent kinase inhibitor 2B (p15
Ink4b) +3.13 +2.13
NM_004091.2 E2F2 E2F transcription factor 2 24.24 22.26
NM_057735.1 CCNE2 cyclin E2 23.22 23.24
NM_001789.2 CDC25A cell division cycle 25 homolog A 22.50 22.45
NM_001798.2 CDK2 cyclin2dependent kinase 2 22.07 21.88
G2/M NM_001237.2 CCNA2 cyclin A2 23.11 23.01
NM_004701.2 CCNB2 cyclin B2 22.65 22.52
NM_001786.2 CDK1 cyclin-dependent kinase 1 22.47 22.63
NM_031966.2 CCNB1 cyclin B1 22.36 22.28
NM_022809.2 CDC25C cell division cycle 25 homolog C 22.27 22.05
doi:10.1371/journal.pone.0013054.t003
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mapped to the library of canonical pathways of the Ingenuity
Pathways Analysis (IPA) database for pathway analysis (IngenuityH
Systems, http://www.ingenuity.com, Mountain View, CA). The
mapped datasets containing either up-regulated or down-regulated
genes in HT29 or GC3/c1 cells with corresponding expression
values were subjected to core analysis that includes overall
canonical pathway enrichment analysis. The significance of
enrichment of genes mapped to different canonical pathways
was calculated by the Fischer’s exact test (p-value) to determine the
probability that the association between the genes and the
canonical pathway could be explained by chance alone. Further,
the ratio between the number of identified genes in a particular
pathway and total number of genes that make up that pathway
provides an estimation of the extent of pathway involvement. The
enriched canonical pathways were ranked by 2log (p-value) as
shown in a histogram of pathway vs. –log (p-value). Datasets
containing both up-regulated and down-regulated genes were also
analyzed in selected pathways pertaining to cell cycle progression
at G1/S and G2/M.
Fold change patterns of most highly DEGs in HT29 and
GC3/c1 were compared by Heat map analysis using Matlab
(Mathworks) software. DEGs analyzed and displayed in the
h e a tm a pd e m o n s t r a t e dad i f f e r e ntial expression p-value of
p,0.001 between control and GANT61 treated cells in both
cell lines.
Quantitative Real-Time PCR (qRT-PCR)
The expression levels of selected genes identified by cDNA
microarray expression profiling at 24 hr following GANT61
treatment, were validated by qRT-PCR. Thus, HT29 or GC3/
c1 cells were either untreated (vehicle control, 0.2% DMSO), or
treated with GANT61 (20 mM) for 0 hr, 16 hr, 24 hr, 38 hr or
48 hr at 37uC, dissolved in DMSO-containing medium. Total
RNA (1 mg) was employed to prepare cDNA via reverse
transcription using the iScript Select cDNA Synthesis Kit (Biorad)
Reverse Transcription System according to manufacturers in-
structions and analyzed using an Applied Biosystems 7500 PCR
Detection System (Applied Biosystems Inc.). All amplifications
were primed by pairs of chemically synthesized 18- to 24- mer
oligonucleotides designed using freely available primer design
software (Primer-BLAST, NCBI) to generate target amplicons of
50–547 bp. All reactions were performed in a final volume of
15 ml. qRT-PCR reaction conditions were as follows: activation at
95uC for 10 min with 40 cycles of denaturation at 95uC for 15 s,
primer annealing and extension at 60uC for 1 min and ramping
back to 95uC. Melt curve analysis of all samples was routinely
performed to ascertain that only the expected products had been
generated. A fluorescence reading determined the extent of
amplification at the end of each cycle. mRNA expression levels
of target genes were normalized to the expression of glyceralde-
hyde phosphate dehydrogenase (GAPDH) and quantified using
the comparative CT method [56]. Q-RT-PCR for each gene was
Table 4. Sequences of primers used in quantitative Real-Time PCR.
Accession # Gene Symbol Strand Primer Sequence Product Size (bp)
NM_078487.2 CDKN2B Plus 59-TCTCCGTTGGCCGGAGGTCA-39 95
Minus 59-TGGCAGGGTCTGCGCAGTTG-39
NM_004701.2 CCNB2 Plus 59-CTAACGGCGCCTCGTACGCT-39 54
Minus 59-CAGGGAGGGACGCGGACTGA-39
NM_057749.1 CCNE2 Plus 59-GAGCGGTAGCTGGTCTGGCG-39 94
Minus 59-GGGCTGGGGCTGCTGCTTAG-39
NM_001789.2 CDC25A Plus 59-CGTGGCTGCCTGCACTCTCA-39 159
Minus 59-GGCTGTCACAGGTGACTGGGG-39
NM_001798.3 CDK2 Plus 59-TTTGCTGAGATGGTGACTCGCCG-39 159
Minus 59-CCGGGCCCACTTGGGGAAAC-39
NM_004091.2 E2F2 Plus 59-CCGGCAGAAGCTGTGTGGGG-39 97
Minus 59-GGCCTCCCTAGGCCCAGCTT-39
NM_001237.3 CCNA2 Plus 59-AAAAGGCAGCGCCCGTCCAA-39 89
Minus 59-CTGCTGCTGCGCTAGACCCC-39
NM_005631.3 CDKN1A Plus 59-CTGCGCCAGCTGAGGTGTGA-39 189
Minus 59-GCTGCTCGCTGTCCACTGGG-39
NM_022809.2 CDC25C Plus 59-GTGCATTTAGCTGGGATGACAATGGAA-39 189
Minus 59-GGCCACTTCTGCTCACCTTTGC-39
NM_001786.2 CDK1 Plus 59-ACTGGCTGATTTTGGCCTTGCC-39 118
Minus 59-TGAGTAACGAGCTGACCCCAGCAA-39
NM_005269 GLI1 Plus 59GCCCAGACAGAGGCCCACTC-39 547
Minus 59CTGCAGCCATCCCAACGGCA-39
NM_005270 GLI2 Plus 59-CACCGCTGCTCAAAGAGAA-39 227
Minus 59-TCTCCACGCCACTGTCATT-39
NM_000264 PTCH1 Plus 59-CCACAGAAGCGCTCCTACA-39 214
Minus 59-CTGTAATTTCGCCCCTTCC-39
doi:10.1371/journal.pone.0013054.t004
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PLoS ONE | www.plosone.org 20 October 2010 | Volume 5 | Issue 10 | e13054Figure 5. Selected DEGs from cDNA array gene expression profiling analyzed by qRT- PCR in HT29 (A) or GC3/c1 (B). Cells were
treated with vehicle alone (0.2% DMSO) or GANT61 (20 mM) for 16 hr, 24 hr, 38 hr, or 48 hr. Total RNA was extracted and qRT-PCR was performed as
described in Materials and Methods using the primer sets listed in Table 2. Data represent the mean6SD of 4 determinations, and GAPDH was used
to normalize the relative mRNA levels.
doi:10.1371/journal.pone.0013054.g005
Figure 6. Schematic representation of genes involved in GANT61-induced inhibition of cell cycle progression. From cDNA microarray,
heat map, and qRT-PCR analyses, genes involved at different phases of the cell cycle including the G1/S transition, and progression through S- G2-
and M- phases, are shown. The genes identified include CDK inhibitors, members of the CDK and CDC families, cyclins, genes involved in DNA
replication and repair, and genes that regulate the mitotic spindle, and involve 5 of the 12 common signaling pathways determined by IPA analysis.
Red: Up-regulated genes. Green: Down-regulated genes. Light shadeRdark shade, increasing differential expression.
doi:10.1371/journal.pone.0013054.g006
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least twice.
Supporting Information
Data S1 HT29 Raw Microarray Data.
Found at: doi:10.1371/journal.pone.0013054.s001 (11.39 MB
XLS)
Data S2 GC3/c1 Raw Microarray Data.
Found at: doi:10.1371/journal.pone.0013054.s002 (11.06 MB
XLS)
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